ADAM17 and non-small cell lung carcinoma: ADAM17 has also been proposed as a target for radiosensitization in non-small cell lung cancer, suggesting that repurposing ADAM17 inhibitors could serve as short-term adjuvants to improve outcomes in radiotherapy settings [63].